Fertility warning
This medicine may affect fertility.
Leaflet MITOXANTRONE TEVA 2mg / ml concentrate for solution for infusion
- Product code:
- W43889002
- Quantity:
- 1
- Indicated for:
- cancer
- Route of administration:
- infusion
- Substance:
- mitoxantrone (antineoplastic agent)
- ATC
- L01DB07 — Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Mitoxantrone is an antineoplastic agent used for the treatment of acute myeloid leukemia, non-Hodgkin's lymphomas, and advanced prostate cancer. It works by intercalating into DNA and inhibiting its synthesis, leading to tumor cell death.
The medication is administered via intravenous infusion, usually in treatment cycles, with the dose adjusted based on the patient's weight and response to therapy. Common side effects include nausea, vomiting, myelosuppression, and alopecia.
Mitoxantrone is contraindicated in patients with severe hepatic impairment or hypersensitivity to the active substance. Its use also requires careful monitoring of cardiac function and blood counts.
This medication is an effective option for the treatment of hematological cancers and other tumor types, helping to improve patient outcomes.
The medication is administered via intravenous infusion, usually in treatment cycles, with the dose adjusted based on the patient's weight and response to therapy. Common side effects include nausea, vomiting, myelosuppression, and alopecia.
Mitoxantrone is contraindicated in patients with severe hepatic impairment or hypersensitivity to the active substance. Its use also requires careful monitoring of cardiac function and blood counts.
This medication is an effective option for the treatment of hematological cancers and other tumor types, helping to improve patient outcomes.
General data about MITOXANTRONE TEVA 2mg / ml
- Substance:
- mitoxantrone
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W43889002
- Concentration:
- 2mg / ml
- Pharmaceutical form:
- concentrate for solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- S — Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Pharmaceutical forms available for mitoxantrone
Concentrations available for mitoxantrone
- 20mg/10ml
- 2mg/ml